StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Intellia Therapeutics

Intellia Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Intellia Therapeutics figures

See a number that looks wrong?